Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

The Comparative Effectiveness Dementia & Alzheimer's Registry (CEDAR) Project

Clinical Trial Details

The Comparative Effectiveness Dementia & Alzheimer's Registry (CEDAR) Project is a prospective registry of adult patients at-risk for, or with, a diagnosis of dementia due to Alzheimer's disease (AD). The purpose of this study is to develop a research repository, or database, for information collected during routine medical care of people with normal memory and family history of AD, or with memory loss or other changes in thinking. The registry will help generate empirical evidence that improves knowledge and informs care decisions about risk reduction for dementia due to AD, and about the effectiveness of a clinical precision medicine intervention. Using a life course approach to comparative effectiveness research will enable investigators to analyze the effects of evidence-based multi-domain interventions on cognition, biomarkers of AD risk, and calculated AD risk across the pre-dementia spectrum of AD.

Key Eligibility: 

Inclusion criteria:

  • 18 years of age or older
  • Family history of Alzheimer's disease and no cognitive complaints OR subjective cognitive decline OR preclinical AD OR mild cognitive impairment due to AD

Exclusion criteria:

  • Diagnosis of moderate-to-severe AD dementia or other dementia
  • Disorders affecting safe engagement in interventions (e.g., malignant disease, major depression, psychotic disorder)
  • Coincident participation in another trial

Eligibility will be reviewed in detail when you contact the study team.

Study contact by location

Upper East Side - Manhattan


Blagovest Nikolov

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:






Open to Enrollment

Age Group